Skip to main content

Table 2 IgG antibody responses (22F-ELISA) against individual pneumococcal vaccine serotypes and cross-reactive serotypes 6A and 19A (ATP immunogenicity cohort)

From: Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial

   PHiD-CV group Control group
PHiD-CV serotypes N % ≥ 0.2 μg/mL (95% CI) GMC, μg/mL (95% CI) N % ≥ 0.2 μg/mL (95% CI) GMC, μg/mL (95% CI)
1 Pre-vaccine 204 19.6 (14.4-25.7) 0.07 (0.06-0.09) 110 18.2 (11.5-26.7) 0.07 (0.06-0.09)
  Post-dose 3 217 100 (98.3-100) 2.69 (2.42-2.99) 108 1.9 (0.2-6.5) 0.03 (0.03-0.03)
4 Pre-vaccine 209 14.8 (10.3-20.4) 0.07 (0.06-0.08) 112 16.1 (9.8-24.2) 0.07 (0.06-0.08)
  Post-dose 3 217 100 (98.3-100) 3.44 (3.06-3.87) 112 2.7 (0.6-7.6) 0.03 (0.03-0.03)
5 Pre-vaccine 210 17.6 (12.7-23.5) 0.07 (0.06-0.08) 111 19.8 (12.9-28.5) 0.07 (0.05-0.08)
  Post-dose 3 217 100 (98.3-100) 4.17 (3.75-4.63) 109 3.7 (1.0-9.1) 0.03 (0.03-0.04)
6B Pre-vaccine 205 21.0 (15.6-27.2) 0.09 (0.07-0.10) 111 31.5 (23.0-41.0) 0.10 (0.08-0.12)
  Post-dose 3 217 82.0 (76.3-86.9) 0.95 (0.76-1.20) 112 1.8 (0.2-6.3) 0.03 (0.03-0.03)
7F Pre-vaccine 207 27.1 (21.1-33.6) 0.09 (0.08-0.11) 111 23.4 (15.9-32.4) 0.08 (0.07-0.10)
  Post-dose 3 217 99.5 (97.5-100) 3.33 (2.99-3.71) 110 1.8 (0.2-6.4) 0.03 (0.03-0.04)
9V Pre-vaccine 208 38.5 (31.8-45.4) 0.13 (0.11-0.16) 110 39.1 (29.9-48.9) 0.15 (0.11-0.19)
  Post-dose 3 217 97.2 (94.1-99.0) 2.39 (2.06-2.76) 112 9.8 (5.0-16.9) 0.04 (0.03-0.05)
14 Pre-vaccine 206 87.9 (82.6-92.0) 0.75 (0.64-0.89) 110 84.5 (76.4-90.7) 0.76 (0.60-0.97)
  Post-dose 3 217 99.1 (96.7-99.9) 3.80 (3.24-4.46) 112 35.7 (26.9-45.3) 0.14 (0.11-0.17)
18C Pre-vaccine 204 36.3 (29.7-43.3) 0.12 (0.10-0.15) 110 34.5 (25.7-44.2) 0.12 (0.09-0.15)
  Post-dose 3 217 99.5 (97.5-100) 10.01 (8.49-11.80) 112 3.6 (1.0-8.9) 0.03 (0.03-0.04)
19F Pre-vaccine 208 68.3 (61.5-74.5) 0.33 (0.28-0.40) 111 68.5 (59.0-77.0) 0.36 (0.29-0.45)
  Post-dose 3 217 98.6 (96.0-99.7) 7.65 (6.55-8.93) 111 22.5 (15.1-31.4) 0.08 (0.07-0.10)
23F Pre-vaccine 202 29.2 (23.0-36.0) 0.08 (0.07-0.10) 108 31.5 (22.9-41.1) 0.10 (0.07-0.12)
  Post-dose 3 217 87.6 (82.4-91.6) 1.10 (0.91-1.33) 112 2.7 (0.6-7.6) 0.03 (0.03-0.04)
Cross-reactive serotypes     
6A Pre-vaccine 208 34.1 (27.7-41.0) 0.13 (0.11-0.15) 112 35.7 (26.9-45.3) 0.14 (0.11-0.18)
  Post-dose 3 217 25.8 (20.1-32.2) 0.09 (0.08-0.11) 108 7.4 (3.3-14.1) 0.04 (0.04-0.05)
19A Pre-vaccine 205 48.3 (41.3-55.4) 0.18 (0.15-0.22) 110 44.5 (35.1-54.3) 0.20 (0.15-0.26)
  Post-dose 3 217 43.8 (37.1-50.7) 0.15 (0.13-0.18) 108 13.9 (8.0-21.9) 0.06 (0.05-0.07)
  1. NOTE. GMC, geometric mean antibody concentration; pre-vaccine, before the first vaccine dose; post-dose 3, 1 month after vaccine dose 3; N, number of subjects with available results (this number varies per time point and per serotype depending on the amount of serum available for testing).